Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Order Of Business For PCORI Methods Panel: Define “Patient-Centered Outcomes Research”

Executive Summary

When the Patient-Centered Outcomes Research Institute's Methodology Committee finished its presentation to PCORI's Board of Governors, one thing became clear: the committee is looking for something broader in its definition of “patient-centered outcomes research” than simply conducting comparative effectiveness research.

You may also be interested in...



A New Framework For Comprehensive Evidence Development

In today’s health care environment, where the volume and complexity of clinical information continues to increase for a range of stakeholders, research sponsors must understand how clinical trials, prospective observational research or registries, and retrospective data are used, what the costs are, and what a combined approach will look like. They must prepare for a more comprehensive and efficient research paradigm that provides payors, providers, and policy makers with the requisite data to make coverage and treatment decisions.

Booz VP Advises Pharma: Show Value To Gain Market Access

Pharma's rapidly changing commercial environment has forced companies to re-think their traditional approaches to marketing.

Booz VP Advises Pharma: Show Value To Gain Market Access

Pharma's rapidly changing commercial environment has forced companies to re-think their traditional approaches to marketing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel